Suzhou, China

Xianbao Liu

This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Peijia Medical (Suzhou) Co., Ltd.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Xianbao Liu. Retrieved from https://idiyas.com/inventor/xianbao-liu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Xianbao Liu

Introduction

Xianbao Liu is an accomplished inventor based in Hangzhou, China. He is currently associated with Hangzhou Valgen Medtech Co., Ltd., where he contributes to advancements in medical technology. Despite having no patents to his name, Liu's work in the field is noteworthy.

Latest Patents

As of now, Xianbao Liu has not registered any patents. This does not diminish his contributions to the industry, as he continues to work on innovative projects within his company.

Career Highlights

Liu has built a career focused on medical technology and innovation. His role at Hangzhou Valgen Medtech Co., Ltd. allows him to collaborate with other talented professionals in the field.

Collaborations

Some of his notable coworkers include Jian'an Wang and Zetao Wang. Their collective expertise contributes to the innovative environment at Hangzhou Valgen Medtech Co., Ltd.

Conclusion

Xianbao Liu is a dedicated inventor whose work in medical technology continues to impact the industry positively. His collaboration with skilled professionals further enhances the potential for future innovations.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…